Etanercept as a salvage treatment for refractory aplastic anemia

Dufour, Carlo, Giacchino, Raffaella, Ghezzi, Pietro, Tonelli, Rossella, Ferretti, Elisa, Pitto, A, Pistoia, Vito, Lanza, Tiziana and Svahn, Johanna (2009) Etanercept as a salvage treatment for refractory aplastic anemia. Pediatric Blood & Cancer, 52 (4). pp. 522-525. ISSN 1545-5009

Full text not available from this repository.


About 10-15% of patients with acquired aplastic anemia (AAA) have resistant/recurrent disease not eligible for standard treatment like hematopoietic stem cell transplantation and/or combined immunosuppression. We report a 17-year-old male with an 11 years history of AAA who, after two courses of immunosuppression, was red cell transfusion-dependent, severely thrombocytopenic, refractory to platelet transfusion, had iron overload and post-transfusion HCV infection. This patient achieved transfusion independence from platelets and normalized Hb after treatment with the anti-TNF agent Etanercept. Over a 12 months follow-up he experienced only transient increase of liver transaminases.

Item Type: Article
Keywords: anti-TNF; complicated aplastic anemia;HCV infection
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Subjects: R Medicine > RM Therapeutics. Pharmacology
Depositing User: Patricia Butler
Date Deposited: 02 Nov 2012 16:20
Last Modified: 05 Oct 2017 18:26
📧 Request an update